Associate Director, Downstream, Manufacturing Sciences and Technology (Biologics)late at Abata Therapeutics

Waltham, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Master’s or PhD degree in biochemistry, biochemical engineering, biotechnology or equivalent
At least 8 years of relevant experience developing, scale-up, and transfer of downstream processes for biologics
Significant experience managing manufacturing in an MSAT environment
Direct hands-on experience with monoclonal antibodies (preferred)
Expertise in purification process optimization with an emphasis on scale-up, scale-down models, process

Responsibilities

Oversee the transfer of manufacturing processes from late-stage development to large-scale production at the CDMOs for multiple programs
Work with CDMOs to identify gaps and implement improvements towards enhancing product quality, robustness, and cost-effectiveness with line of sight to commercial manufacturing
Build strong relationships and partner cross-functionally with process development, analytical, formulation, quality, regulatory, and program management
Oversee GMP manufacturing campaigns ensuring seamless execution, timely completion, and handoff to drug product manufacturing teams
Partner with late-stage process characterization and MSAT teams and develop robust control strategy enabling successful PPQ DS campaigns
Serve as person-in-plant (PIP) during drug substance manufacturing campaigns
Partner with stakeholders to support timely approval and execution of reports, batch records, in-process sampling plans, review SOPs, change controls, deviations, OOS/OOT investigations, and CAPAs
Support regulatory filings by authoring high quality reports enabling timely submissions for multiple jurisdictions (INDs, CTAs)
Perform MFG/MSAT risk assessment activities in a phase-appropriate manner ensuring proper measures are in place in support of production and filing requirements
20-25% travel in support of manufacturing activities at CDMOs

Skills

Downstream Processing

MSAT

Biologics Manufacturing

Process Development

Scale-up

Process Transfer

Process Validation

BLA Filing

Regulatory Compliance

Data Analysis

Troubleshooting

GMP

Tech Transfer

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free